LB1092 Topical omiganan for severe papulopustular rosacea: A randomized, vehicle-controlled, double-blind, multicenter study

Abstract

Brentuximab vedotin is a monoclonal anti-CD30 antibody-drug conjugate that has been used to treat a variety of CD30+ neoplasms. The phenomenon of antigen loss has been observed in patients treated with the anti-CD20 antibody rituximab. This study seeks to assess for antigen loss in the setting of recurrent CD30+ neoplasms treated with brentuximab vedotin. We report 9 cases of persistent/recurrent cutaneous CD30+ lymphoid neoplasms that demonstrated variable CD30 expression after treatment with brentuximab vedotin. Cases include mycosis fungoides (n¼6), cutaneous T cell lymphoma, not otherwise specified (n¼1), and anaplastic large cell lymphoma, both primary (n¼1) and systemic (n¼1). Immunohistochemical staining revealed decreased CD30 expression following brentuximab vedotin therapy in 7 of 9 cases. In these 7 cases, the pre-treatment percent of tumor cells staining for CD30 ranged from 10-100% (mean 50.0%, SD 27.8%), compared to 5-50% (mean 14.5%, SD 14.8%, p¼0.003) at recurrence. This case series highlights the finding that CD30 positivity can be variable in recurrences after treatment with anti-CD30 antibodies. This serves to raise awareness of the phenomenon of antigen loss after treatment with brentuximab vedotin and underscores the utility of performing multiple biopsies and/or employing molecular diagnostic techniques in patients with recurrent/persistent disease.

Exploring the Pathogenesis and Mechanism-Targeted Treatments of Rosacea: Previous Understanding and Updates

“…In this randomized, double-blind, vehiclecontrolled, parallel-group, multicenter study, patients who received omiganan gel exhibited a significant decrease in the mean inflammatory lesion counts and lower IGA scores, indicating significant improvement in the severity of their PPR. Importantly, omiganan gel was well-tolerated, and no serious adverse events were reported [253].…”

Exploring the Pathogenesis and Mechanism-Targeted Treatments of Rosacea: Previous Understanding and Updates

“…In this randomized, double-blind, vehicle-controlled, parallel-group, multicenter study, patients who received omiganan gel exhibited a significant decrease in the mean inflammatory lesion counts and lower IGA scores, indicating significant improvement in the severity of their PPR. Importantly, omiganan gel was well-tolerated, and no serious adverse events were reported [ 253 ].…”